An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Sapanisertib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 05 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 05 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.